Price Alert

Amylyx Pharmaceuticals In... (AMLX)

NASDAQ: AMLX · Real-Time Price · USD

9.77

-0.18 (-1.81%)

At close: Sep 05, 2025, 1:04 PM

Amylyx Pharmaceuticals Statistics

Share Statistics

Amylyx Pharmaceuticals has 89.17M shares outstanding. The number of shares has increased by 30.93% in one year.

Shares Outstanding	89.17M
Shares Change (YoY)	30.93%
Shares Change (QoQ)	0.61%
Owned by Institutions (%)	81.29%
Shares Floating	66.52M
Failed to Deliver (FTD) Shares	37
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 7.43M, so 8.34% of the outstanding shares have been sold short.

Short Interest	7.43M
Short % of Shares Out	8.34%
Short % of Float	9.2%
Short Ratio (days to cover)	8.35

Valuation Ratios

The PE ratio is -0.85 and the forward PE ratio is -6.43. Amylyx Pharmaceuticals's PEG ratio is 0.

PE Ratio	-0.85
Forward PE	-6.43
PS Ratio	2.95
Forward PS	11004.2
PB Ratio	1.56
P/FCF Ratio	-1.53
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Amylyx Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.67, with a Debt / Equity ratio of 0.01.

Current Ratio	6.67
Quick Ratio	6.67
Debt / Equity	0.01
Debt / EBITDA	-0.01
Debt / FCF	-0.01
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$710.33K
Profits Per Employee	$-2.45M
Employee Count	123
Asset Turnover	0.45
Inventory Turnover	n/a

Taxes

Income Tax	-393K
Effective Tax Rate	0.13%

Stock Price Statistics

The stock price has increased by 352.27% in the last 52 weeks. The beta is -0.45, so Amylyx Pharmaceuticals's price volatility has been lower than the market average.

Beta	-0.45
52-Week Price Change	352.27%
50-Day Moving Average	8.02
200-Day Moving Average	5.21
Relative Strength Index (RSI)	67.64
Average Volume (20 Days)	1,778,332

Income Statement

In the last 12 months, Amylyx Pharmaceuticals had revenue of 87.37M and earned -301.74M in profits. Earnings per share was -4.43.

Revenue	87.37M
Gross Profit	-37.26M
Operating Income	-314.73M
Net Income	-301.74M
EBITDA	-290.98M
EBIT	-291.88M
Earnings Per Share (EPS)	-4.43

Full Income Statement

Balance Sheet

The company has 77.39M in cash and 1.98M in debt, giving a net cash position of 75.41M.

Cash & Cash Equivalents	77.39M
Total Debt	1.98M
Net Cash	75.41M
Retained Earnings	-606.69M
Total Assets	194.6M
Working Capital	165.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -167.65M and capital expenditures -157K, giving a free cash flow of -167.8M.

Operating Cash Flow	-167.65M
Capital Expenditures	-157K
Free Cash Flow	-167.8M
FCF Per Share	-2.46

Full Cash Flow Statement

Margins

Gross margin is -42.65%, with operating and profit margins of -360.22% and -345.36%.

Gross Margin	-42.65%
Operating Margin	-360.22%
Pretax Margin	-345.81%
Profit Margin	-345.36%
EBITDA Margin	-333.03%
EBIT Margin	-360.22%
FCF Margin	-192.06%

Dividends & Yields

AMLX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AMLX is $12, which is 20.6% higher than the current price. The consensus rating is "Buy".

Price Target	$12
Price Target Difference	20.6%
Analyst Consensus	Buy
Analyst Count	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	11.56
Piotroski F-Score	2